Reviewer’s report

**Title:** Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer

**Version:** 1  **Date:** 24 October 2010

**Reviewer:** Christian Weiss

**Reviewer’s report:**

**Discretionary Revisions::**

**Results part:**

Treatment: It is stated that 74% of the patients completed treatment as planned. This is not in accordance to the following data on the applicability of concurrent chemotherapy, because just 48 patients (56%) received the planned UFT/LV dose. Compared to other phase III trials, e.g. the German CAO/ARO/AIO-94 and the French FFCD 9203, concurrent chemotherapy could be given completely in 89% and 93% of patients, respectively. Please clearly and comment on this. Might this be due to the strict requirements on dose adjustments in the protocol?

**Level of interest:** An article of importance in its field

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

'I declare that I have no competing interests'